List view / Grid view

Anthony Davies

Filter the results

 

article

Screening In-Depth Focus 2013

In this Screening In-Depth Focus: New approaches to cell based…

30 July 2013 | By

In this Screening In-Depth Focus: New approaches to cell based assays for high content screening and analysis; Reduce, reuse, recycle: how drug repositioning is finding its niche in drug discovery; Workshop Review: Biochemical assays for screening. Screening roundtable...

article

A reduction to practise for siRNA screening utilising high conent analysis (HCA) technologies

One of the major limitations of performing large-scale High Content…

10 July 2012 | By Anthony Mitchell Davies & Anne Marie Byrne, Department of Clinical Medicine Trinity College Dublin; Holger Erfle, BIOQUANT-Zentrum Ruprecht-Karls-Universität Heidelberg; Graham Donnelly, Rita Murray & Peadar MacGabhann, Biocroi Ltd

One of the major limitations of performing large-scale High Content Analysis (HCA) screens is reagent cost, indeed this fact has been a key driver in the development of assay size reduction strategies here at The Irish National Centre for High Content Screening and Analysis at Trinity College’s Department of Medicine.…

article

Cancer biology where do we go next?

The World Cancer Report (2008) predicts a 50% worldwide increase…

22 February 2010 | By

The World Cancer Report (2008) predicts a 50% worldwide increase in cancer incidence by 2030, predicting 75 million people living within a five year diagnosis of cancer1. This increase is partially fuelled by significant medical advances in developed countries ensuring people live longer. However, it is also attributable to developing…

article

High Content Analysis Roundtable

1. How significantly do you feel the Drug Discovery Process…

29 May 2009 | By

1. How significantly do you feel the Drug Discovery Process has benefited from the application of High Content Analysis techniques? Anthony Davies: Since the mid 1990's High-content analysis (HCA) has primarily been used in the later stages of the pre-clinical drug discovery process. However, as HCA techniques have developed and…

article

Development of cardiac cell based assays for study of cardiac disease – in with the new by automating the old

Approximately 45% of all deaths and 50% of all hospitalisations…

3 December 2008 | By

Approximately 45% of all deaths and 50% of all hospitalisations in the western world are a direct result of cardiovascular disease. Cardiomyocyte hypertrophy is a mechanism by which myocardial mass is increased to compensate for any elevated physical demands placed upon the heart, thus ensuring that adequate perfusion of body…

article

Utilisation of secondary screening

European Pharmaceutical Review has brought together four individuals from different…

19 June 2008 | By

European Pharmaceutical Review has brought together four individuals from different sides of the scientific palette to discuss current and future issues surrounding secondary screening and maximising its potential.

article

Automated workflow optimisation and assay development strategies for High Content Research Facility, Trinity College Dublin

High Content Screening (HCS) is becoming increasingly utilised as an…

23 November 2007 | By

High Content Screening (HCS) is becoming increasingly utilised as an early drug-discovery and basic research tool for defining the functions of genes, proteins and other biomolecules in normal and abnormal cellular functions. HCS involves the integration of a number of preparation steps which include; cell-sample preparation, fluorescent labelling, image acquisition,…